Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Organisation › Details

CRISPR Therapeutics (Group)

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. *

 

Period Start 2013-01-01 established
Product Industry CRISPR gene editing technology
Persons Person Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
  Person 2 Foy, Shaun (CRISPR Therapeutics 201404 CFO + Co-Founder + ERS Genomics CEO + Co-Founder before Nomura Phase4 Ventures)
     
Region Region Basel BS
  Country Switzerland
  Street 36 Aeschenvorstadt
  City 4051 Basel
    Address record changed: 2015-05-10
     
Basic data Currency USD
  Annual sales 3,124,000 (revenue, collaboration, consolidated (2018) 2018-12-31)
  Profit -164,981,000 (2018-12-31)
  Cash 456,649,000 (2018-12-31)
     
    * Document for �About Section�: CRISPR Therapeutics AG. (6/24/16). "Press Release: CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing". Basel & Cambridge, MA.
     
   
Record changed: 2019-03-11

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for CRISPR Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px




» top